Ad-p53

DRUG2 trials

Sponsors

MultiVir, Inc.

Conditions

LymphomaMetastatic Solid Tumor CancerRecurrent Head and Neck CancerSolid Tumor

Phase 1

Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer

TerminatedNCT02842125

MultiVir, Inc.Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer

Start: 2018-11-20End: 2020-05-08Updated: 2020-06-02

Phase 2

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

MultiVir, Inc.Lymphoma, Solid Tumor

Start: 2018-10-01End: 2022-12-31Target: 40Updated: 2020-06-09

Related Papers

Effect of adenoviral p53 (Ad-p53) tumor suppressor immune gene therapy on checkpoint inhibitor resistance and abscopal therapeutic efficacy.

Journal of Clinical Oncology2017-05-205 citations